top of page
Search

FDA approves Latuda for Bipolar Depression in Youth

  • Mark W. Wilson, MD
  • Jul 31, 2018
  • 1 min read

"In March 2018, the US Food and Drug Administration approved the antipsychotic drug lurasidone (Latuda) for the treatment of bipolar depression in children and adolescents aged 10–17 years. Lurasidone was already approved for adults with bipolar depression, as an add-on treatment to the mood stabilizers lithium and valproate, and for schizophrenia in people aged 13 years and up.A 6-week clinical trial in 347 youth compared lurasidone (in doses ranging from 20 to 80 mg/day) to placebo and found that those who received lurasidone showed significant improvements in depression compared to those who received placebo. The average dose was below 40 mg/day. The research by Melissa P. DelBello and colleagues was published in the Journal of the American Academy of Child and Adolescent Psychiatry in 2017.In the study, lurasidone was well-tolerated. Side effects included nausea, sleepiness, minimal weight gain, and insomnia. Lurasidone did not seem to affect glucose, triglycerides, cholesterol, or blood pressure.

 
 
 

Recent Posts

See All
New Phone Numbers AND New Address

My NEW routine, non-emergency office number is now (917) 566-5798; the old number, (917) 441-2344, will no longer be used. My NEW...

 
 
 
April Vacation

I will be out of the country from April 9 – April 17, 2022. Please keep in mind the following: If you require refills while I am away,...

 
 
 
Single Post: Blog_Single_Post_Widget
bottom of page